Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Português | Pусский | Suomi | Svenska | US
Euro Huntington's disease network [logo]
EHDN2016 DISEASE NETWORK REGISTRY PROJECTS LOGIN
 
 
  
Experimental Rx -
--->Nyheter
[-]Prosjektet
--->Sponsor
--->[-]Hovedstyre
--->Arnesen
--->Blumenstein
--->Burgunder
--->Craufurd
--->Humbert
--->Jones
--->Kremer
--->Reilmann
--->Roos
--->Rosser
--->Weydt
--->Capper-Loup
--->Feihle
--->Levey
--->McLean
--->Offentlige Dokumenter
--->[-]Writing Committee Strategic ...
--->Dates
--->[+]Scientific Review Committee
--->Sentralkoordinering
--->Språkkoordinering
--->Fellowship Programme
--->[-]Constitution
--->Article 1
--->Article 2
--->Article 3
--->Article 4
--->Article 5
--->Article 6
--->Article 7
--->Article 8
--->Article 9
--->Article 10
--->Article 11
--->Article 12
--->Documents
--->[+]Voting/Nomination
--->[-]Medlemskap
--->Anmodning
[-]Foskningssteder
--->[+]Østerrike
--->[+]Belgia
--->[+]Tsjekkiske republikk
--->[+]Danmark
--->[+]Finland
--->[-]Frankrike
--->Coordination
--->HD Associations
--->Amiens
--->Bordeaux
--->Documents
--->[+]Clermont-Ferrand
--->Lille
--->[+]Rouen
--->Strasbourg
--->[+]Tyskland
--->[+]Ireland
--->[+]Italia
--->[+]Nederland
--->[+]Norge
--->[+]Poland
--->[+]Portugal
--->[+]Russia
--->[-]Spania
--->Coordination
--->HD Associations
--->Alicante
--->Badajoz
--->Barcelona - Bellvitge
--->Barcelona - Clinic i Provincia...
--->Barcelona - Mutua de Terra...
--->Barcelona - Santa Creu i Sa...
--->Barcelona - Merced
--->Bilbao
--->Burgos
--->Canaries
--->Granada
--->Fuenlabrada
--->[+]Madrid-BTCIEN
--->Madrid - Clínico
--->Madrid - FJD
--->Madrid - RyC
--->Murcia
--->Oviedo
--->Palma de Mallorca
--->Pamplona
--->Santiago
--->Sevilla
--->Sevilla-HUVRocio
--->Sevilla-St-Ana
--->Valencia
--->Zaragoza
--->[+]Sverige
--->[+]Sweits
--->[-]Storbrittania
--->Coordination
--->HD Associations
--->Links
--->[+]UKHDN
--->Standard of Care
--->Aberdeen
--->[+]Ayr
--->Belfast
--->Birmingham
--->[+]Blandford Forum
--->Bristol
--->Cambridge
--->Cardiff
--->Dundee
--->Edinburgh
--->Exeter
--->Fife
--->Forth Valley
--->Glasgow
--->Gloucester
--->Hull
--->Inverness
--->Launceston
--->Leeds
--->Leicester
--->Liverpool
--->London - Guy's Hospital
--->London - Hammersmith
--->London - NHNN
--->London - Royal Hospital
--->London - St. George´s
--->Manchester
--->Newcastle-Upon-Tyne
--->[+]Northampton
--->Nottingham
--->Oxford
--->[+]Plymouth
--->Poole
--->Preston
--->Reading
--->[+]Sheffield
--->Southampton
--->Stoke-on-Trent
--->Swindon
--->Contacts
--->Dates
--->[+]Documents
--->Wrexham
--->[+]Utenfor Europa
[-]Arbeidsgrupper
--->[-]Advanced HD
--->Dates
--->[+]Meetings
--->[-]Behavioural Phenotype
--->Dates
--->[+]Meetings
--->[+]Psycho appr. & interv. Sub...
--->[+]Biologisk Modifiserende Fakto...
--->[-]Biomarkører
--->[+]Dates
--->[+]Meetings
--->[+]Brain and Tissue Banking
--->[-]Kognitiv Fenotype
--->[-]Dates
--->[+]Meetings
--->[-]Environmental Modifiers
--->[+]Dates
--->[+]Meetings
--->[-]Funksjonell Vurdering
--->Dates
--->[+]Meetings
--->[+]Genetisk Testing
--->[-]Genetisk Modifiserende Fakto...
--->[+]Dates
--->[+]Meetings
--->[+]Helseøkonomi
--->[-]Bildteknikk
--->[+]Dates
--->[+]Meetings
--->[-]Juvenile HS
--->Dates
--->[-]Motorisk Fenotype
--->[+]Dates
--->[+]Meetings
--->[-]Neurobeskyttende Behandlin...
--->[+]Dates
--->[+]Meetings
--->[-]Fysioterapi
--->Dates
--->[+]Meetings
--->[-]Livskvalitet
--->[-]Dates
--->[+]Meetings
--->[-]Omsorgsstandard
--->[+]Dates
--->[+]Meetings
--->[+]Dieticians
--->[+]SALT
--->[+]Dental care
--->[+]Occupational
--->[-]Kirurgiske Terapaier
--->Dates
--->[+]Meetings
--->[-]Symptomatiske Behandling
--->[-]Dates
--->[+]Meetings
--->[+]Young Adults
[-]Begivigheter
--->[+]EHDN 2016
--->EHDN 2014
--->Announcement
--->Introduction
--->Registration
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->CME points
--->Sponsoring
--->Travel Information
--->Hotel Booking
--->Reimbursement
--->Social Activities
--->[+]Abstract Submission
--->Contacts
--->Feedback
--->[-]EHDN 2012
--->Introduction
--->Announcement
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Important Dates
--->Registration
--->[+]Travel & Accommodation
--->[+]EHA Registration
--->EHA Programme
--->Reception Dinner
--->About Stockholm
--->[+]Abstract Submission
--->Reimbursement
--->[-]Documents
--->Handouts
--->Presentations
--->[-]Posters
--->Pathogenic mechanisms
--->Animal models
--->Choreatic disorders - no...
--->Genetic modifiers
--->Wet Biomarkers
--->Imaging
--->Clin characteristics
--->Clin char-motor
--->Clin char-cognitive
--->Clin char - behaviour
--->Clin char-other
--->Clinical studies
--->Genetic testing
--->Clinical care
--->Experimental Rx
--->Clinical Rx
--->Non-scientific
--->Contacts
--->Feedback & Evaluation
--->[-]EHDN 2010
--->Introduction
--->Programme I
--->Programme II
--->Additional Meetings
--->Registration
--->EHA Programme
--->[+]EHA Registration
--->Plenary Dinner
--->Social Programme
--->Important Dates
--->[+]Abstract Submission
--->Reimbursement
--->Hotel Booking
--->[+]Travel and Location
--->[+]About Prague
--->Documents
--->Committees
--->Contact
--->Feedback & Evaluation
--->[+]EHDN 2008
--->[+]EHDN 2007
--->[+]EHDN 2006
--->[+]EHDN 2005
--->[-]EHDN 2004
--->Introduction
--->Final Programme
[-]Kontakt
--->Kontaktskjema
--->Chatte-rom
--->Mailing-lister
--->Nyhetsbrev
--->Jobb Tilbud
datobeskrivelsestørrelseforfatter dokument 
04.08.26In vivo efficacy of (CUG)n oligonucleotides to treat HD32 kBanonymousapplication/mswordp02-in-vivo-efficacy-oligonucleotides 
04.08.26Antisense oligonucleotide mediated transcript reduction and modulation – the European approach to develop a therapy for Huntington Disease32 kBanonymousapplication/mswordp01-antisense-oligonucleotide-transcript 
04.08.26Reducing toxic n-terminal Huntingtin fragments in HD using exon skipping32 kBanonymousapplication/mswordp03-exon-skipping 
04.08.26A Huntingtin peptide inhibits polyQ-hHtt associated defects32 kBanonymousapplication/mswordp04-polyq-hhtt-associated-defects 
04.08.26Astrocytes affect neuroprotection: Glatiramer acetate in Huntington`s Disease therapy32 kBanonymousapplication/mswordp07-glatiramer-acetate 
04.08.26Olesoxime improves specific features of the HD pathology32 kBanonymousapplication/mswordp06-olesoxime 
04.08.26Analysis of Nrf2-downstream targets after fumarate treatment in dorsal root ganglia – an anti-inflammatory therapy in neurodegenerative disease?!32 kBanonymousapplication/mswordp08-analysis-of-nrf2 

Fil innholder 7 dokumenter.
about us | privacy statement | disclaimer | terms of use